Breast Cancer Vaccine Works Against Deadlier Form of Disease

It reduced mortality among women with HER2 malignancies, study shows

By Amanda Gardner
HealthDay Reporter

Related Encyclopedia • Adenocarcinoma of the Lung and Brain Metastases • Amenorrhea • Amniocentesis • Amniocentesis and CVS More... Related Healthscout Videos Nutrition and Cancer Nutrition and Osteoporosis Nature’s Remedies Controlling Incontinence More... Related Animations • Breast Reduction • Breast Self-Exam Video • Colon Cancer • Erectile Dysfunction More... Related Drug Information • Actonel • Detrol LA • Diflucan • Ditropan XL More... Related News Articles • Women and Men Urged to Seek 'Preconception Care' • Donor's Age Not Linked to Poor Outcomes in Liver Transplants • More Cancer Lymph Nodes Analyzed at Specialty Centers • Lidocaine Gel May Ease Mammography Discomfort More...

SUNDAY, April 13 (HealthDay News) -- A breast cancer vaccine significantly reduced the risk of recurrence for patients who have a high expression of the protein HER2-neu.

This type of breast cancer, representing about one-quarter of all cases, tends to be deadlier than other forms of the disease. In this group, the vaccine reduced mortality by 50 percent.

Text Continues Below

---

Even better, however, the vaccine lowered mortality by 100 percent in women with breast cancer and low or intermediate expression of HER2/neu. Currently, these women have no therapies other than conventional cancer treatments such as surgery and chemo.

"We now have something we think works in the majority of women with breast cancer who are currently underserved," said Dr. George Peoples, senior author of the study, which is expected to be presented at the American Association for Cancer Research annual meeting, in San Diego. "It's also very, very well-tolerated, like a flu shot."

Peoples is chief of surgical oncology at Brooke Army Medical Center in San Antonio and director of the Cancer Vaccine Development Program at the U.S. Military Cancer Institute.

According to study lead author, Dr. Linda Benavides, a resident in general surgery at Brooke Army Medical Center, the biotech firm, Apthera, has licensed the vaccine, named it NeuVax, and is currently planning phase 3 clinical trials.

But there's still no guarantee the vaccine will reach the market.

"It is a very exciting area of research, but it's very exploratory and not ready for prime time," said Dr. Minetta Liu, a translational researcher/breast oncologist at Georgetown's Lombardi Comprehensive Cancer Center.

Other cancer vaccines have been tested, mostly to treat tumors that have already spread, with little success.

"We've been studying vaccines in the setting of metastatic cancer, but the immune system has already been effective, and the cat's out of the bag already," Liu said. "Many of us believe the time to get rid of them is as they're developing. It's just so hard to study it in that setting."

Page:  1 | 2 | Next >>